Celyad Oncology

(OTC) CLYYF

Current Price$0.25

Market Cap$11.19M

Since IPO (2014)-100%

5 Year-97%

1 Year-62%

1 Month-29%

Celyad Oncology Financials at a Glance

Market Cap

$11.19M

Revenue (TTM)

€207.00K

Net Income (TTM)

-€5.00M

EPS (TTM)

$0.03

P/E Ratio

8.36

Dividend

$0.00

Beta (Volatility)

-0.92 (Low)

Dividend

$0.00

Beta (Volatility)

-0.92 (Low)

Price

$0.25

Volume

8,063

Open

$0.25

Price

$0.25

Volume

8,063

Open

$0.25

Previous Close

$0.25

Daily Range

$0.25 - $0.25

52-Week Range

$0.15 - $0.53

Estimated Earnings Date

Sep 23, 2026

Dividend

$0.00

Beta (Volatility)

-0.92 (Low)

Price

$0.25

Volume

8,063

Open

$0.25

Previous Close

$0.25

Daily Range

$0.25 - $0.25

52-Week Range

$0.15 - $0.53

Estimated Earnings Date

Sep 23, 2026

CLYYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celyad Oncology

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Matthew R. Kane, MBA

Website

www.celyad.com

Headquarters

Mont-Saint-Guibert, 1435, BE

CLYYF Financials

Key Financial Metrics (TTM)

Gross Margin

92%

Operating Margin

-342%

Net Income Margin

38%

Return on Equity

Return on Capital

-3%

Return on Assets

19%

Earnings Yield

11.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.19M

Shares Outstanding

44.76M

Volume

8.06K

Avg. Volume

125.984

Financials (TTM)

Gross Profit

€1.93M

Operating Income

-€7.18M

EBITDA

-€7.01M

Operating Cash Flow

-€6.90M

Capital Expenditure

€0.00

Free Cash Flow

-€6.90M

Cash & ST Invst.

€1.71M

Total Debt

€0.00

Celyad Oncology Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

€7.00K

-87.9%

Gross Profit

€2.13M

+6349.3%

Gross Margin

304.17%

N/A

Market Cap

$11.19M

N/A

Market Cap/Employee

$658.26K

N/A

Employees

N/A

Net Income

€4.50M

+195.7%

EBITDA

-€3.58M

+19.9%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

€1.71M

-65.7%

Total Debt

€0.00

-100.0%

Accounts Receivable

€791.70K

+23.3%

Inventory

€0.00

N/A

Long Term Debt

€0.00

-100.0%

Short Term Debt

€0.00

-100.0%

Return on Assets

18.73%

N/A

Return on Invested Capital

-2.90%

N/A

Free Cash Flow

-€3.62M

+51.4%

Operating Cash Flow

-€3.62M

+47.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KPRXKiora Pharmaceuticals, Inc.

KPRXKiora Pharmaceuticals, Inc.$2.59-0.38%

PSTVPlus Therapeutics, Inc.

PSTVPlus Therapeutics, Inc.$5.20-4.06%

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$4.29-8.72%

SONNSonnet BioTherapeutics Holdings, Inc.

SONNSonnet BioTherapeutics Holdings, Inc.$1.26-59.35%

HILSHillstream BioPharma, Inc.

HILSHillstream BioPharma, Inc.$0.24+5.66%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.01+0.00%

BWVBlue Water Vaccines, Inc.

BWVBlue Water Vaccines, Inc.$0.18-6.97%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.91+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.88-0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

INTCIntel

INTCIntel$125.62+0.07%

NOKNokia

NOKNokia$15.00+0.06%

NVDANvidia

NVDANvidia$205.22+0.00%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.45-0.05%

Questions About CLYYF

What is the current price of Celyad Oncology?

Celyad Oncology is trading at $0.25 per share.

What is the 52-week range for Celyad Oncology?

Over the past 52 weeks, Celyad Oncology has traded between $0.15 and $0.53.

How much debt does Celyad Oncology have?

As of the most recent reporting period, Celyad Oncology reported total debt of €0.00.

How much cash does Celyad Oncology have on hand?

Celyad Oncology reported €2.01M in cash and cash equivalents in its most recent financial results.

What is Celyad Oncology’s dividend yield?

Celyad Oncology does not currently have a dividend yield.

Celyad Oncology

Celyad Oncology Financials at a Glance

CLYYF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Celyad Oncology

CLYYF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Celyad Oncology Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CLYYF

What is the current price of Celyad Oncology?

What is the 52-week range for Celyad Oncology?

How much debt does Celyad Oncology have?

How much cash does Celyad Oncology have on hand?

What is Celyad Oncology’s dividend yield?

Premium Investing Services